Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRA
826
DELISTED
ProAssurance
PRA
| $18.9M | 0.03% |
336,500
+3,700
| +1% | +$205K |
|
|
PEI
827
DELISTED
Pennsylvania Real Estate Investment Trust
PEI
| $18.9M | 0.03% |
66,420
-25,200
| -28% | -$7.53M |
|
|
NGD
828
DELISTED
New Gold Inc
NGD
| $18.9M | 0.03% |
5,394,200
-2,480,600
| -32% | -$9.42M |
|
|
INXN
829
DELISTED
Interxion Holding N.V.
INXN
| $18.9M | 0.03% |
538,100
+104,200
| +24% | +$3.71M |
|
|
YDKN
830
DELISTED
Yadkin Financial Corporation
YDKN
| $18.8M | 0.03% |
550,022
-75,500
| -12% | -$2.29M |
|
831
First Horizon
FHN
$12.3B
| $18.8M | 0.03% |
941,581
+683,700
| +265% | +$12M |
|
832
Onto Innovation
ONTO
$20.6B
| $18.8M | 0.03% |
749,500
+249,900
| +50% | +$5.72M |
|
|
Y
833
DELISTED
Alleghany Corp
Y
| $18.7M | 0.03% |
30,785
-1,415
| -4% | -$789K |
|
|
SMI
834
DELISTED
Semiconductor Manufacturing Intl
SMI
| $18.7M | 0.03% |
2,451,600
+2,100
| +0.1% | +$13.6K |
|
835
Bio-Techne
TECH
$11.3B
| $18.7M | 0.03% |
726,000
+152,000
| +26% | +$3.99M |
|
|
RP
836
DELISTED
RealPage, Inc.
RP
| $18.6M | 0.03% |
621,600
-60,000
| -9% | -$1.67M |
|
837
Mercury Insurance
MCY
$5.84B
| $18.6M | 0.03% |
309,000
+4,500
| +1% | +$256K |
|
838
Black Hills Corp
BKH
$5.58B
| $18.6M | 0.03% |
303,200
+36,400
| +14% | +$2.17M |
|
|
BSTC
839
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $18.5M | 0.03% |
332,746
+30,884
| +10% | +$1.48M |
|
840
Popular Inc
BPOP
$11.2B
| $18.5M | 0.03% |
422,825
+23,700
| +6% | +$959K |
|
841
Micron Technology
MU
$1.07T
| $18.5M | 0.03% |
844,736
+792,436
| +1,515% | +$14.9M |
|
|
HTZ
842
DELISTED
Hertz Global Holdings, Inc.
HTZ
| $18.5M | 0.03% |
988,272
-723,472
| -42% | -$18.1M |
|
|
CUTR
843
DELISTED
Cutera, Inc.
CUTR
| $18.4M | 0.03% |
1,063,260
+17,860
| +2% | +$267K |
|
844
New York Times
NYT
$10.3B
| $18.4M | 0.03% |
1,384,400
+189,800
| +16% | +$2.35M |
|
845
RPM International
RPM
$14.7B
| $18.4M | 0.03% |
341,300
-239,900
| -41% | -$12.3M |
|
|
BRKL
846
DELISTED
Brookline Bancorp
BRKL
| $18.3M | 0.03% |
1,118,600
+173,100
| +18% | +$2.47M |
|
847
Entegris
ENTG
$24.6B
| $18.3M | 0.03% |
1,023,390
+358,700
| +54% | +$6.22M |
|
848
SouthState Bank Corp
SSB
$10.8B
| $18.3M | 0.03% |
209,483
+63,800
| +44% | +$5.16M |
|
849
Calix
CALX
$2.51B
| $18.2M | 0.03% |
2,368,200
+117,000
| +5% | +$852K |
|
|
MNR
850
DELISTED
Monmouth Real Estate Investment Corp
MNR
| $18.2M | 0.03% |
1,196,500
+357,100
| +43% | +$4.94M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.